Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Leukemia
•
Hematology
Is there any role of Venetoclax as a single agent therapy in MDS?
Related Questions
What is your current approach to maintenance therapy in FLT3-mutant AML post allogeneic HCT?
How should one approach an incidentally found T-cell gene arrangement?
How has your approach to utilizing MRD-guided therapy in previously untreated CLL changed since the FLAIR trial, particularly in choosing between continuous versus time-limited treatment?
Would you offer intensive CNS prophylaxis to Ph negative B-ALL patients who have possible mandibular nerve involvement on MRI face?
How long do you continue ATRA during induction in high risk acute promyelocytic leukemia?
How would you manage an elderly patient with mild pancytopenia who refuses bone marrow biopsy and whose flow cytometry is suggestive of CMML/MDS?
Would you consider TKI discontinuation in a patient who has negative BCR transcripts on Bosutinib?
What is your approach to re-challenging BTK inhibitors for a patient who has had intolerance to several different agents?
How do you dose arsenic in a super-morbid person (>500 lbs) with APML?
Would concurrent CRLF2/IgH rearrangement affect your treatment recommendations for an adult patient with Ph+ p190 high risk (Age>35, WBC >30) B-cell ALL that was started on induction therapy with ponatinib + blinatumomab?
